Press Releases

GlobeNewswire, Inc.

SINGAPORE, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), an integrated infrastructure provider of efficient altcoin mining and staking, today announced that it will release its financial results...

GlobeNewswire, Inc.

SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close.

EIN Presswire

Prospective FDA IDE pivotal study evaluated self-forming magnetic compression anastomosis with immediate lumen across six U.S. centers.

GlobeNewswire, Inc.

HAUPPAUGE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Orbit International Corp. (OTCID Basic Market:ORBT), an electronics manufacturer and software solution provider, today announced that its Power Group (“OPG”) recorded bookings in excess of...

GlobeNewswire, Inc.

Quincy, MA, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Stran & Company, Inc. ("Stran" or the "Company") (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive...

GlobeNewswire, Inc.

ADJUSTED EBITDA OF $128 MILLION, FREE CASH FLOW OF $32 MILLION AND RETURN ON CAPITAL EMPLOYED OF 15.4% STRONG OPERATIONAL VISIBILITY WITH ES BACKLOG INCREASING TO $1.5 BILLION AT THE END OF Q2/26 ORGANIC GROWTH CAPEX FORECASTED AT TOP END OF...

GlobeNewswire, Inc.

London, Aug. 06, 2026 (GLOBE NEWSWIRE) -- RedCloud Holdings plc (Nasdaq: RCT) (“RedCloud” or the “Company”), the company building intelligent infrastructure for global trade, today announced that it has joined as a co-signatory of the Open Weights...

GlobeNewswire, Inc.

LAS VEGAS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Live Ventures Incorporated (NASDAQ: LIVE) (“Live Ventures” or the “Company”), a diversified holding company, will issue its financial results for its fiscal third quarter ended June 30, 2026, before the...

GlobeNewswire, Inc.

Operational Highlights for the Second Quarter of 2026 The SEC declared Deep Isolation Nuclear, Inc.'s registration statement on Form S-1 effective on May 7, 2026, allowing the common stock of the Company to be freely tradable Surpassed 100 issued...

GlobeNewswire, Inc.

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; topline data from multiple...

GlobeNewswire, Inc.

Immunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM trial for previously treated...

GlobeNewswire, Inc.

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on...

GlobeNewswire, Inc.

CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (BCMA TCE) multi-dose regimen data in SLE in Q4 2026; Phase 1/2 basket study in autoimmune cytopenias to...

GlobeNewswire, Inc.

Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 Concluded last patient last visit in CANYON-1 Phase 1b study (n=240) of CRB-913 in...

GlobeNewswire, Inc.

Tetra4, a subsidiary of Renergen and the developer of the Virginia Gas Project, has entered into an additional take-or-pay contract to supply liquified natural gas (LNG) to a domestic food processor, establishing a multi-year contracted cash flow...

GlobeNewswire, Inc.

Generated second quarter 2026 revenue of $64.8 million with record high Commercial IoT subscriber activations.

GlobeNewswire, Inc.

One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting Initial Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug...

GlobeNewswire, Inc.

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral...

GlobeNewswire, Inc.

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026...

GlobeNewswire, Inc.

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027 Mid-cycle meeting completed for relutrigine;...